Literature DB >> 16761881

Surveillance for febrile respiratory infections during Cobra Gold 2003.

Julie Fuller1, Keith Hanley, Robert Schultz, Michael Lewis, Nikki E Freed, Michael Ellis, Viseth Ngauy, Richard Stoebner, Margaret Ryan, Kevin Russell.   

Abstract

The Naval Health Research Center conducted laboratory-based surveillance for febrile respiratory infections at the 2003 Cobra Gold Exercise in Thailand. Seventeen individuals met the case definition for febrile respiratory illness, and diagnostic specimens were obtained from 16. Laboratory testing identified influenza A for 44%; sequence analysis demonstrated that these were Fujian-like influenza strains, which represented the predominant strain found globally in 2003/2004. Other pathogens identified included coronavirus OC43, respiratory syncytial virus, and rhinovirus. Logistical challenges were overcome as laboratory-supported febrile respiratory illness surveillance was conducted during a military training exercise. With heightened concern over the potential for another global influenza pandemic, such surveillance could prove critical for the detection of emerging influenza and respiratory pathogen strains with potential for importation to the United States.

Entities:  

Mesh:

Year:  2006        PMID: 16761881      PMCID: PMC7110301          DOI: 10.7205/milmed.171.5.357

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Global Infectious Disease Surveillance at DoD Overseas Laboratories, 1999-2007.

Authors:  J Jeremy Sueker; Jean-Paul Chretien; Joel C Gaydos; Kevin L Russell
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

2.  Risk factors for febrile respiratory illness and mono-viral infections in a semi-closed military environment: a case-control study.

Authors:  Junxiong Pang; Jing Jin; Jin Phang Loh; Boon Huan Tan; Wee Hong Victor Koh; Sock Hoon Ng; Zheng Jie Marc Ho; Qiuhan Gao; Alex R Cook; Li Yang Hsu; Vernon J Lee; Mark I Cheng Chen
Journal:  BMC Infect Dis       Date:  2015-07-25       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.